Skip to content
Brand AI

Exelixis

Recent events

Recent events tied to this brand in public sources.

Back to profile1 entries

  1. 2021

    FDA approves Cabometyx for certain thyroid cancer patients

    The FDA approved Exelixis's cabozantinib tablet, marketed as Cabometyx, for patients aged 12 years and older with previously treated radioactive iodine-refractory differentiated thyroid cancer.

    Source